


Claficapavir

Cat. No.:	HY-145560		
CAS No.:	2055732-24-4		
Molecular Formula:	C ₁₇ H ₁₂ ClNO ₄ S ₂		
Molecular Weight:	393.86		
Target:	HIV		
Pathway:	Anti-infection		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



SOLVENT & SOLUBILITY

In Vitro

DMSO : 200 mg/mL (507.79 mM; ultrasonic and warming and heat to 40°C)

Concentration	Mass		
	1 mg	5 mg	10 mg
1 mM	2.5390 mL	12.6949 mL	25.3897 mL
5 mM	0.5078 mL	2.5390 mL	5.0779 mL
10 mM	0.2539 mL	1.2695 mL	2.5390 mL

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

Claficapavir (A1752) is a specific nucleocapsid protein (NC) inhibitor with an IC₅₀ around 1 μM. Claficapavir strongly binds the HIV-1 NC (K_d=20 nM) thereby inhibiting the chaperone properties of NC and leading to good antiviral activity against the HIV-1^[1].

IC₅₀ & Target

HIV-1

In Vitro

Claficapavir binds directly to HIV-1 NC, thereby inhibiting specific chaperone functions of NC including Psi RNA dimerization and complementary trans-activation response element (cTAR) DNA destabilization, and it also disrupts the proper Gag processing^[1].

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

REFERENCES

[1]. Kim MJ, et al. Identification and characterization of a new type of inhibitor against the human immunodeficiency virus type-1 nucleocapsid protein. *Retrovirology*. 2015;12:90. Published 2015 Nov 6.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA